Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Viatris
Deal Size : $415.0 million
Deal Type : Acquisition
Details : TYRVAYA® (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : $415.0 million
March 01, 2023
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Viatris
Deal Size : $415.0 million
Deal Type : Acquisition
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
Details : TYRVAYA® (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2022
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Acquisition
Details : With the combination of Viatris' R&D and regulatory capabilities, along with Oyster Point's commercial asset, Tyrvaya (varenicline), for the treatment of dry eye disease, the Company has the foundation to create a leading global ophthalmology franchise.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 11, 2022
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TYRVAYA® (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2022
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TYRVAYA® (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TYRVAYA (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TYRVAYA Nasal Spray is believed to bind to cholinergic receptors to activate the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ji Xing Pharmaceuticals
Deal Size : $222.3 million
Deal Type : Licensing Agreement
Oyster Point Pharma Ink Exclusive License Agreement with Ji Xing Pharmaceuticals for OC-01 and OC-02
Details : Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for patients with dry eye disease in Greater China.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : $17.5 million
May 08, 2021
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ji Xing Pharmaceuticals
Deal Size : $222.3 million
Deal Type : Licensing Agreement
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The NDA submission for OC-01, is based on efficacy and safety results from a comprehensive clinical trial program conducted in patients with a broad range of dry eye disease.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2020
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from the Phase 2 IMPERIAL study illustrate OC-01 nasal spray caused a decrease in goblet cell size, as compared to placebo, indicating mucin secretion after a single administration.
Product Name : Tyrvaya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2020
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable